TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
COPENHAGEN, Denmark--(BUSINESS WIRE)--Apr 29, 2024--
Source: eagletribune.com
Page 2 - Priority Review Designation News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Priority Review Designation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Priority Review Designation Today - Breaking & Trending Today
GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer
/PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food...
Source: prnewswire.com
GenFleet Therapeutics Announces Broad-spectrum Activity of GFH547, an Oral panRAS (ON) Inhibitor, and Its Potential to Overcome Resistance against SIIP-based KRAS Inhibitors in Late-breaking Research Abstract of 2024 AACR Annual Meeting
SHANGHAI and SAN DIEGO, April 9, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in
Source: thailand-business-news.com
GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting
SHANGHAI and SAN DIEGO, April 9, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in
Source: thailand-business-news.com
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
Acquisition transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025 Acquisition adds taletrectinib, a next-generation,...
Source: marketscreener.com